Earnings call transcript: PetVivo lifts revenue in Q1 2026, but stock stays flat
PetVivo reported a 13% increase in first-quarter revenue to $338,000, while its net loss narrowed to $0.05 per share. The veterinary medical device company credits its higher-margin SPRYNG product and cost reductions for the improvement. Distributor revenue made up about 82% of total sales. The company has shifted focus to the proprietary SPRYNG product, which helped lift margins and reduce dependence on outside products.
Operating loss narrowed 13% to $1.6 million, and total operating expenses fell 10% to $1.8 million. Despite the gains, PetVivo remains pre-profitable, trading at $0.97, about unchanged and well below its 52-week high. Analysts view the company as overvalued and in a pre-profitability stage with limited cash reserves. Management expects continued revenue growth and improved margins as they expand sales teams, enter Canada, and develop new products.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
